Filing Flows › Organogenesis Holdings (ORGO) › Q3 2026 › vs Q2 2026
Organogenesis Holdings (ORGO) Q3 2026 vs Q2 2026 (quarter over quarter)
Organogenesis Holdings's revenue rose $1.7M (+4%) from $43.8M in Q2 2026 to $45.5M in Q3 2026.
Organogenesis Holdings, Q3 2026: revenue $45.5M (-70% year over year), operating margin -64.9%, net loss $29.6M, operating cash flow −$18.6M. The chart draws each line against Q2 2026, the increases inside each band.
Every line
| Line | Q3 2026 | Q2 2026 | Change | % |
|---|---|---|---|---|
| Revenue | $45.5M | $43.8M | $1.7M | +4% |
| Net loss | $29.6M | $96.3M | −$66.6M | -69% |
| Costs & expenses | $75.1M | $140M | −$65.0M | -46% |
| Operating costs | $74.9M | $94.7M | −$19.8M | -21% |
| Income tax | $8K | $45.4M | −$45.4M | -100% |
| Research & development | $8.0M | $18.3M | −$10.3M | -56% |
| SG&A | $45.1M | $54.0M | −$8.9M | -16% |
| Other operating costs | $21.9M | $22.5M | −$587K | -3% |
| Operating cash sources | $29.6M | $96.3M | −$66.6M | -69% |
| Depreciation & amortization | $3.9M | $3.7M | $259K | +7% |
| Share-based compensation | $2.8M | $3.1M | −$246K | -8% |
| Working capital & other | $4.3M | $57.9M | −$53.6M | -93% |
| Cash used in operations | $18.6M | $31.7M | −$13.1M | -41% |
| Net loss absorbed | $29.6M | $96.3M | −$66.6M | -69% |
Questions
How much did Organogenesis Holdings's revenue grow quarter over quarter in Q3 2026?
Organogenesis Holdings's revenue rose $1.7M (+4%) from $43.8M in Q2 2026 to $45.5M in Q3 2026.